Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Return on Assets: 2018-2019

Historic Return on Assets for Monopar Therapeutics (MNPR) over the last 2 years, with Dec 2019 value amounting to -0.47%.

  • Monopar Therapeutics' Return on Assets fell 5.00% to -0.47% in Q4 2019 from the same period last year, while for Dec 2019 it was -0.47%, marking a year-over-year decrease of 5.00%. This contributed to the annual value of -0.42% for FY2019, which is 4.00% down from last year.
  • Latest data reveals that Monopar Therapeutics reported Return on Assets of -0.47% as of Q4 2019, which was up 37.72% from -0.75% recorded in Q3 2019.
  • Monopar Therapeutics' 5-year Return on Assets high stood at -0.36% for Q3 2018, and its period low was -1.96% during Q2 2018.
  • Over the past 2 years, Monopar Therapeutics' median Return on Assets value was -0.60% (recorded in 2019), while the average stood at -0.87%.
  • Within the past 5 years, the most significant YoY rise in Monopar Therapeutics' Return on Assets was 130bps (2019), while the steepest drop was 39bps (2019).
  • Quarterly analysis of 2 years shows Monopar Therapeutics' Return on Assets stood at -0.42% in 2018, then decreased by 5bps to -0.47% in 2019.
  • Its last three reported values are -0.47% in Q4 2019, -0.75% for Q3 2019, and -0.66% during Q2 2019.